Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Bladder Cancer”

439 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 439 results

Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Study completedNCT04602078
What this trial is testing

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Who this might be right for
Locally Advanced or Metastatic Urothelial Carcinoma
Spanish Oncology Genito-Urinary Group 82
Testing effectiveness (Phase 2)Study completedNCT00002914
What this trial is testing

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Eastern Cooperative Oncology Group 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03854474
What this trial is testing

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaStage III Bladder Cancer AJCC v8+1 more
National Cancer Institute (NCI) 30
Not applicableStudy completedNCT00253708
What this trial is testing

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Cancer
Beth Israel Deaconess Medical Center 39
Testing effectiveness (Phase 2)Study completedNCT00585689
What this trial is testing

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Who this might be right for
Bladder Cancer
University of Michigan Rogel Cancer Center 29
Testing effectiveness (Phase 2)Study completedNCT02643303
What this trial is testing

Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Who this might be right for
Head and Neck Squamous Cell CarcinomaBreast CancerSarcoma+8 more
Ludwig Institute for Cancer Research 58
Early research (Phase 1)Looking for participantsNCT04485013
What this trial is testing

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Who this might be right for
Cancer
Tizona Therapeutics, Inc 240
Testing effectiveness (Phase 2)Active Not RecruitingNCT04644068
What this trial is testing

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Who this might be right for
Ovarian CancerBreast CancerPancreatic Cancer+10 more
AstraZeneca 702
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Early research (Phase 1)Looking for participantsNCT04389632
What this trial is testing

Sigvotatug Vedotin in Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer 1,006
Early research (Phase 1)Study completedNCT03884556
What this trial is testing

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Who this might be right for
Solid TumorLymphoma
Trishula Therapeutics, Inc. 56
Testing effectiveness (Phase 2)Looking for participantsNCT05706129
What this trial is testing

Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+6 more
ITM Oncologics GmbH 270
Early research (Phase 1)Looking for participantsNCT03740256
What this trial is testing

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Who this might be right for
Bladder CancerHead and Neck Squamous Cell CarcinomaCancer of the Salivary Gland+7 more
Baylor College of Medicine 45
Early research (Phase 1)Study completedNCT02318329
What this trial is testing

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsGastric CancerTransitional Cell Carcinoma of the Bladder
Five Prime Therapeutics, Inc. 79
Early research (Phase 1)Study completedNCT02144051
What this trial is testing

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Who this might be right for
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
AstraZeneca 32
Testing effectiveness (Phase 2)Study completedNCT00080795
What this trial is testing

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
M.D. Anderson Cancer Center 65
Early research (Phase 1)Study completedNCT03330561
What this trial is testing

PRS-343 in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 85
Testing effectiveness (Phase 2)Active Not RecruitingNCT00365157
What this trial is testing

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+4 more
National Cancer Institute (NCI) 132
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Load More Results